| CPC C12Q 1/6883 (2013.01) [A61K 31/404 (2013.01); A61K 45/06 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)] | 22 Claims |
|
1. A method comprising:
contacting a sample from a subject in need thereof having diabetes that has or is suspected of having a neurodegenerative disease with a capture molecule, wherein the capture molecule is configured to specifically bind to a biomarker and wherein the biomarker is gas5 (SNHG2);
detecting specific binding of the biomarker to the capture molecule;
quantifying an amount of the biomarker that is specifically bound to the capture molecule; and
administering a therapeutically effective amount of a compound, wherein the compound having a structure of formula 1
![]() wherein R1 is a methyl, an isobutane, a phenyl, an indole, or a butanamine,
wherein R2 is an ethylbenzene, an ethylcyclohexane, an isopentane, a phenyl, a propanamine, or a methylcyclopropane,
wherein R3 is a methylcyclopropane, a propionic acid, an ethylbenzene, or a propanamine
wherein R4 is a butanamine, a propionic acid, or a phenyl,
wherein R5 is a methylcyclopropane, a propionic acid, or an ethylbenzene,
wherein R6 is a phenyl, a propionic acid, an isobutene, and
wherein R7 is a phenyl, a propionic acid, a butanamine, or a methyl;
or a pharmaceutical formulation thereof, to the subject in need thereof.
|